150 related articles for article (PubMed ID: 21631420)
81. Therapeutic Potential of Neuregulin in Cardiovascular System: Can we Ignore the Effects of Neuregulin on Electrophysiology?
Wang X; Liu Z; Duan HN; Wang L
Mini Rev Med Chem; 2016; 16(11):867-71. PubMed ID: 26902151
[TBL] [Abstract][Full Text] [Related]
82. Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart.
Klement GL; Goukassian D; Hlatky L; Carrozza J; Morgan JP; Yan X
Front Pharmacol; 2012; 3():113. PubMed ID: 22754526
[TBL] [Abstract][Full Text] [Related]
83. Strategies for targeting the cardiac sarcomere: avenues for novel drug discovery.
Holmes JB; Doh CY; Mamidi R; Li J; Stelzer JE
Expert Opin Drug Discov; 2020 Apr; 15(4):457-469. PubMed ID: 32067508
[No Abstract] [Full Text] [Related]
84. Future g protein-coupled receptor targets for treatment of heart failure.
Rengo G; Lymperopoulos A; Koch WJ
Curr Treat Options Cardiovasc Med; 2009 Aug; 11(4):328-38. PubMed ID: 19627665
[TBL] [Abstract][Full Text] [Related]
85. Novel Molecular Approaches in Heart Failure: Seven Trans-Membrane Receptors Signaling in the Heart and Circulating Blood Leukocytes.
Schiattarella GG; Magliulo F; Cattaneo F; Gargiulo G; Sannino A; Franzone A; Oliveti M; Perrino C; Trimarco B; Esposito G
Front Cardiovasc Med; 2015; 2():13. PubMed ID: 26664885
[TBL] [Abstract][Full Text] [Related]
86. Neuregulin as a heart failure therapy and mediator of reverse remodeling.
Galindo CL; Ryzhov S; Sawyer DB
Curr Heart Fail Rep; 2014 Mar; 11(1):40-9. PubMed ID: 24234399
[TBL] [Abstract][Full Text] [Related]
87. Novel therapies in acute and chronic heart failure.
Aronson D; Krum H
Pharmacol Ther; 2012 Jul; 135(1):1-17. PubMed ID: 22475446
[TBL] [Abstract][Full Text] [Related]
88. Neuregulin-1 signaling in the pathogenesis of chemotherapy-induced heart failure.
Lenneman CG
Curr Heart Fail Rep; 2014 Jun; 11(2):134-8. PubMed ID: 24682830
[TBL] [Abstract][Full Text] [Related]
89. Heart failure with preserved ejection fraction: emerging drug strategies.
Zouein FA; de Castro Brás LE; da Costa DV; Lindsey ML; Kurdi M; Booz GW
J Cardiovasc Pharmacol; 2013 Jul; 62(1):13-21. PubMed ID: 23714774
[TBL] [Abstract][Full Text] [Related]
90. When conventional heart failure therapy is not enough: angiotensin receptor blocker, direct renin inhibitor, or aldosterone antagonist?
Bangalore S; Kumar S; Messerli FH
Congest Heart Fail; 2013; 19(3):107-15. PubMed ID: 23241032
[TBL] [Abstract][Full Text] [Related]
91. Cartilage regeneration in zebrafish depends on Nrg1/ErbB signaling pathway.
Sapède D; Bahraoui S; Abou Nassif L; Barthelaix A; Mathieu M; Jorgensen C; Djouad F
Front Cell Dev Biol; 2023; 11():1123299. PubMed ID: 37215080
[No Abstract] [Full Text] [Related]
92. Metformin alleviates ethanol-induced cardiomyocyte injury by activating AKT/Nrf2 signaling in an ErbB2-dependent manner.
Chen Y; Zhu S; Lin Z; Zhang Y; Jin C; He S; Chen X; Zhou X
Mol Biol Rep; 2023 Apr; 50(4):3469-3478. PubMed ID: 36765018
[TBL] [Abstract][Full Text] [Related]
93. Targeting cardiomyocyte proliferation as a key approach of promoting heart repair after injury.
Li S; Ma W; Cai B
Mol Biomed; 2021 Nov; 2(1):34. PubMed ID: 35006441
[TBL] [Abstract][Full Text] [Related]
94. Angiogenic Endothelial Cell Signaling in Cardiac Hypertrophy and Heart Failure.
Gogiraju R; Bochenek ML; Schäfer K
Front Cardiovasc Med; 2019; 6():20. PubMed ID: 30895179
[TBL] [Abstract][Full Text] [Related]
95. Dysregulation of Neuregulin-1/ErbB signaling in the hippocampus of rats after administration of doxorubicin.
Liao D; Guo Y; Xiang D; Dang R; Xu P; Cai H; Cao L; Jiang P
Drug Des Devel Ther; 2018; 12():231-239. PubMed ID: 29430172
[TBL] [Abstract][Full Text] [Related]
96. Cell death mechanisms of the anti-cancer drug etoposide on human cardiomyocytes isolated from pluripotent stem cells.
Nemade H; Chaudhari U; Acharya A; Hescheler J; Hengstler JG; Papadopoulos S; Sachinidis A
Arch Toxicol; 2018 Apr; 92(4):1507-1524. PubMed ID: 29397400
[TBL] [Abstract][Full Text] [Related]
97. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
[TBL] [Abstract][Full Text] [Related]
98. Neuregulin protects human umbilical vein endothelial cell via activating CD98hc through MAPK pathway.
He S; Zhang J; Qi X; Wang D; Wang X; Zhou S
Int J Clin Exp Med; 2015; 8(5):6702-12. PubMed ID: 26221208
[TBL] [Abstract][Full Text] [Related]
99. Relationship between clinical data and gene expression in the HER2/ErbB2-dependent signaling pathway in patients with acute heart failure.
Szmit S; Jank M; Maciejewski H; Balsam P; Łój M; Filipiak KJ; Motyl T; Opolski G
J Appl Genet; 2013 Nov; 54(4):447-53. PubMed ID: 23975515
[TBL] [Abstract][Full Text] [Related]
100. Mechanism-based engineering against anthracycline cardiotoxicity.
Force T; Wang Y
Circulation; 2013 Jul; 128(2):98-100. PubMed ID: 23757311
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
